Roche announced today that William Pao, M.D., Ph.D., Professor of Medicine and Head of the Hematology-Oncology Division at Vanderbilt University Medical Center in the US, will join Roche Pharma Research and Early Development (pRED) as Global Head of the Oncology Disease and Translational Area.
Genentech, a member of the Roche Group, announced today that an independent data monitoring...
Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this...
In response to advances in technology and the increasing needs of society, Roche has implemented a broader data sharing policy. The company's new policy provides access to summary data in the form of clinical study reports (CSRs), and analyzable patient level data sets
Strong demand for its cancer medicines and diagnostic tests used by clinical laboratories boosted Swiss drug maker Roche's full-year profits, the company reported Thursday.
Prothena Corporation announced today that, pursuant to its License, Development, and Commercialization Agreement with Roche, it will receive the $30 million upfront payment from Roche as a result of the License Agreement having become effective upon the expiration of the Hart-Scott-Rodino waiting period.
Roche today announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints.
Roche and Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.
Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin ® biologics conjugated to toxic agents developed at Roche for the treatment of cancer.
Swiss voters soundly rejected on Sunday a proposal to limit the pay of companies' highest-paid managers to 12 times that of their lowest-paid workers. Switzerland is home to global business players such as pharmaceutical companies Novartis and Roche; insurance groups Zurich and Swiss Re; and banks UBS and Credit Suisse.
The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.
The agreement will focus on the research, clinical development and commercialization of a number of new tumour-associated peptide (TUMAP)-based cancer vaccine candidates and other immunotherapies in oncology, targeting primarily gastric, prostate and non-small cell lung cancer.
Polyphor Ltd, a privately held pharmaceutical company, and Roche announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.
Amgen today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014.
Roche Holding AG has reported a 6 percent increase in overall sales for the first nine months of the year helped by strong demand for its established and new cancer drugs. The Basel, Switzerland-based company said that its group sales over three quarters rose to 34.9 billion Swiss francs ($38.2 billion), up from 33.7 billion francs in the same time period last year.
Roche today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in Penzberg (Germany), Basel (Switzerland), as well as Vacaville and Oceanside (USA).
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair ® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H 1 -antihistamine therapy at approved doses.
Swiss drugmaker Roche said Friday it is tapping Lufthansa CEO Christoph Franz to serve as its next board chairman. The company, based in Basel, Switzerland, said that Franz would be nominated to succeed the current board chairman, Franz Humer, in a vote at the annual shareholders' meeting in early March.
A biotech drug from Roche moved one step closer to becoming the first medicine approved to treat breast cancer before surgery. The FDA 's panel of cancer experts voted 13-0, with one abstention, that the benefits of Perjeta as an initial treatment for breast cancer outweigh its risks.
The FDA has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery. In documents posted online, FDA scientists said women who received the drug Perjeta as initial treatment for breast cancer were more likely to be cancer-free at the time of surgery than women who received older drug combinations.
Inovio Pharmaceuticals Inc. could earn more than $400 million through a partnership with Swiss drugmaker Roche Holding AG to develop potential vaccines that target prostate cancer and hepatitis B.
Roche has announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment.
Roche Holding AG posted an 11 percent rise in first-half profit Thursday boosted by strong sales of its blockbuster cancer drugs.
Shares of Alexion Pharmaceuticals Inc. jumped Friday on media reports that Swiss drugmaker Roche is considering a buyout of the smaller Connecticut-based drugmaker.
Roche today announced that following the results of a regular safety review of the aleglitazar AleCardio phase III trial, the independent Data and Safety Monitoring Board (DSMB) has recommended to halt the trial due to safety signals and lack of efficacy.
Genentech has announced that the FDA has accepted the company's Biologics License Application (BLA) for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia (CLL), one of the most common forms of blood cancer.
Genentech, a member of the Roche Group, today announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for the use of a Perjeta® (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.
Halozyme Therapeutics said that its development partner Roche has received a positive recommendation from a European drug regulator for the administration of a breast cancer drug by subcutaneous injection. Halozyme's stock jumped 24 percent.
- Page 1